M Philippe MARQUET

Rhumatologue

RPPS 10002069457

📊 Reconnaissance scientifique : 11/100📝 91 articles publiés🇫🇷 Publications académiques françaises (8)

✨ Génération du profil synthétique IA en cours…

Activité de recherche & publications

Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.

Influence scientifique

11 articles ont été cités au moins 11fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil

Arthritis and rheumatism · 2010

📚 82 citations🎯 RCR 2.87Top 17% NIH

Lire l'abstract Crossref ↓

AbstractObjectiveMycophenolic acid (MPA) is the active metabolite of mycophenolate mofetil (MMF), which is widely used to treat systemic lupus erythematosus (SLE). In transplantation, MPA area under the plasma concentration–time curve from 0 to 12 hours (MPA AUC0–12) is correlated with clinical outcome. We undertook the present study to assess possible relationships between SLE activity and MPA AUC0–12.MethodsUsing a Bayesian estimator, MPA AUC0–12 was determined in 71 consecutive SLE patients (61 women and 10 men; mean ± SD age 34 ± 10 years) receiving a stable MMF dose. On the same day, SLE activity was assessed using the SLE Disease Activity Index (SLEDAI; active disease defined as a SLEDAI score ≥6) and the British Isles Lupus Assessment Group (BILAG) index (active disease defined as BILAG A or B).ResultsTwo groups were studied: patients with active SLE (mean ± SD SLEDAI score 11.6 ± 4.4; n = 26) and patients with inactive SLE (mean ± SD SLEDAI score 1.9 ± 1.6; n = 45). MPA AUC0–12 correlated weakly with the dose of MMF (r = 0.33, P = 0.005). Mean ± SD MPA AUC0–12 in the group with active SLE was significantly lower than that in the group with inactive SLE (26.8 ± 13.6 μg.hour/ml versus 46.5 ± 16.3 μg.hour/ml; P < 0.0001). MPA AUC0–12 was negatively correlated with the SLEDAI (r = –0.64, P < 0.0001). In multivariate analysis, MPA AUC0–12 was the sole parameter associated with SLE activity (odds ratio 0.89 [95% confidence interval 0.83–0.96], P = 0.002). The MPA AUC0–12 threshold value of 35 μg.hour/ml was associated with the lowest risk of active SLE.ConclusionOur data show that SLE activity is strongly correlated with MPA AUC0–12. An individualized dosing regimen of MMF, with a target AUC0–12 of 35 μg.hour/ml, should be considered for SLE patients.

Pharmacokinetic study of mycophenolate mofetil in patients with systemic lupus erythematosus and design of Bayesian estimator using limited sampling strategies

Clinical pharmacokinetics · 2008

📚 45 citations🎯 RCR 1.68🩺 Clinique

Pharmacokinetics of mycophenolate mofetil in children with lupus and clinical findings in favour of therapeutic drug monitoring

British journal of clinical pharmacology · 2014

📚 43 citations🎯 RCR 2.18Top 24% NIH🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

AimsThe use of mycophenolate mofetil (MMF) in children with systemic lupus erythematosus (SLE) is increasing. However, the clinical benefit of its monitoring has been scarcely studied, and little is known about its pharmacokinetics in this context. The objectives of the present study were: (i) to describe mycophenolic acid (MPA, the active moiety of MMF) pharmacokinetics, (ii) to develop a Bayesian estimator (BE) allowing the determination AUC (area under the curve) from a limited number of blood samples and (iii) to explore the relationships between exposure indices to MPA and the clinical status in children with SLE.MethodsThis was a retrospective study including 36 children with SLE, extracted from the expert system ISBA, for whom full‐ pharmacokinetic profiles of MPA were collected together with clinical data. A pharmacokinetic model and a BE were developed using an iterative two stage Bayesian approach. ROC curve analyses and logistic regressions were used to investigate the association of exposure and active disease.ResultsA pharmacokinetic model and a BE were developed that allowed good AUC estimation performance (bias ± SD = −0.02 ± 0.15). ROC curve analyses showed that AUC/dose <0.06 and AUC <4 mg l−1 h were associated with a good sensitivity and specificity for active disease (78%/94% and 94%/56%, respectively). When introduced in a logistic regression model, AUC <44 mg l−1 h and AUC/dose <0.06 were associated with an increased risk of active disease (OR = 21.2, 95% CI 2.3, 196.1, P = 0.007 and OR = 59.5, 95% CI 5.9, 588.2, P = 0.0005 respectively].ConclusionsThe developed pharmacokinetic BE could be used to test prospectively the interest of MPA monitoring for limiting relapse of the disease or its progression.

Cookies & analyse de trafic

M Philippe MARQUET

Pourquoi vous devez consulter ce praticien

Activité de recherche & publications

Publications académiques en France

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Articles de presse (2)

Top publications · les plus citées

Publications scientifiques (10) — classées par pathologie

Transversal4

csDMARDs2

Lupus2

Pédiatrie2

Partager cette fiche